FdaApplication
BLA 103552
Identifiers
- fda_app_no: BLA103552
Properties
| Property | Value |
|---|---|
| applicant_name | Merck Sharp & Dohme LLC |
| application_type | BLA |
| approval_date | 1995-03-17 |
Revenue by product
VARIVAX
| Period | Revenue |
|---|---|
| Q2 2026 | $592.0M |
| Q1 2026 | $538.0M |
| Q4 2025 | $619.0M |
| Q3 2025 | $684.0M |
| Q2 2025 | $609.0M |
| Q1 2025 | $539.0M |
| Q4 2024 | $594.0M |
| Q3 2024 | $703.0M |
| Q2 2024 | $617.0M |
| Q1 2024 | $570.0M |
| Q4 2023 | $545.0M |
| Q3 2023 | $713.0M |
| Q2 2023 | $582.0M |
| Q1 2023 | $528.0M |
| Q4 2022 | $525.0M |
| Q3 2022 | $668.0M |
| Q2 2022 | $578.0M |
| Q1 2022 | $470.0M |
| Q4 2021 | $509.0M |
| Q3 2021 | $661.0M |
| Q2 2021 | $516.0M |
| Q1 2021 | $449.0M |
| Q4 2020 | $488.0M |
| Q3 2020 | $576.0M |
| Q2 2020 | $378.0M |
| Q1 2020 | $435.0M |
| Q4 2019 | $481.0M |
| Q3 2019 | $623.0M |
| Q2 2019 | $675.0M |
| Q1 2019 | $496.0M |
| Q4 2018 | $455.0M |
| Q3 2018 | $525.0M |
| Q2 2018 | $426.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (2)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| VARIVAX | — | NLT 1350PFU/.5ML | For Injection |
| VARIVAX | — | NLT 1350PFU/.5ML | For Injection |
2 products